XORTX Therapeutics Re-engages IR Agency LLC for Investor Relations

CALGARY, Alberta, Sept. 08, 2026 /CourierPR/ -- XORTX is a pharmaceutical company focusing on the development of multiple clinically advanced products. The company's lead program, XRx-026, is aimed at treating gout, while XRx-008 targets ADPKD ( Autosomal Dominant Polycystic Kidney Disease). Additionally, XRx-101 is in development for acute kidney and other acute organ injuries associated with respiratory virus infections. The company is also advancing XRx-225, a preclinical-stage program for Type 2 diabetic nephropathy, and the recently acquired VB4-P5 program, which targets both rare and prevalent forms of kidney disease.

XORTX’s mission is to develop medications that improve the quality of life and health of individuals suffering from gout and other significant diseases. The company’s re-engagement with IR Agency LLC underscores its ongoing commitment to maintain robust communication with its investor base and the broader medical community.

According to the terms of the new agreement, IR Agency LLC will provide investor relations and marketing services on the same basis as previously disclosed in the company’s news releases dated May 19, 2026, and August 28, 2026. These services include the distribution of news to relevant investors and stakeholders, as well as strategic marketing initiatives designed to support the company’s growth and development.

The re-engagement with IR Agency LLC comes as XORTX continues to navigate the complexities of the pharmaceutical industry, including regulatory compliance and market positioning. The company remains dedicated to advancing its product pipeline and addressing the needs of patients suffering from chronic and acute kidney diseases.